May 04, 2026 | SCOTUS Restores Mifepristone Mail Access; First PROTAC Drug Wins FDA Approval

Supreme Court grants emergency stay restoring mifepristone access — and the ruling's implications hit every drugmaker's risk model. Plus: Arvinas/Pfizer's vepdegestrant becomes the first PROTAC approved by the FDA, UCB acquires Candid Therapeutics for $2.2B in autoimmune bispecifics, and Cytokinetics' pivotal HCM readout lands tomorrow.Visit us at www.thepharmacloseout.compharma, pharmaceutical, FDA, clinical trials, biotech, drug approvals, healthcare, pharma podcast, The Pharma Closeout, mifepristone, Supreme Court, PROTAC, vepdegestrant, Veppanu, Arvinas, Pfizer, UCB, Candid Therapeutics, bispecific antibodies, autoimmune, Teva, Emalex, ecopipam, Tourette syndrome, Ligand, XOMA, royalty, Incyte, Jakafi XR, ruxolitinib, Axsome, Auvelity, Alzheimer's agitation, Celcuity, gedatolisib, breast cancer, Cytokinetics, aficamten, HCM, Samsung Biologics, Windward Bio, Amgen, Novartis, oral GLP-1, Foundayo, Wegovy, AbbVie, Regeneron